Stein Steven H

INCY Chief Medical Officer Steven Stein sold 15.6K shares at $101.70, reducing stake to 34.2K shares amid 30.5% 90-day gain.

Steven Stein, EVP & Chief Medical Officer, sold 15,634 shares of Incyte at $101.70 on January 5, 2026, reducing his holdings by 31.4% to 34,203 shares. The transaction occurred while the stock trades near its 52-week high of $110.57, having gained 30.5% over the prior 90 days and 14.3% over the past 30 days. At this same ticker, Stein's prior two sales on December 1-2 saw negative 30-day returns of -4.1% and -3.6% respectively, suggesting recent volatility. His cross-ticker track record shows a 50% well-timed rate on 7 prior sells with modest average returns, though measurable outcomes at Incyte itself are limited for his most recent transactions. The company fundamentals remain solid with $1.4B revenue, $424.2M net income, and 14.8% annual growth, though the 18.28 P/E is elevated given recent price momentum.

EVP & CMO Steven H Stein sells 22,664 shares at $102.56 avg for $2.3M, reducing stake by 26.4%

Steven H Stein, Incyte's EVP & Chief Medical Officer, executed two separate sales on consecutive days (December 1–2, 2025) totaling 22,664 shares for $2,324,438.19 at a blended average price of $102.56. This represents a significant 26.4% reduction in his holdings from 85,793 to 63,129 shares. The sales occurred near the 52-week high of $108.26, with the current price at $101.50. Looking at his same-ticker history at INCY, his prior 4 measurable sales showed mixed timing: two generated positive 90-day returns (sales were poorly timed; stock rose after he sold) while two generated negative returns (sales were well-timed). His cross-ticker track record shows a 50% well-timed rate on prior sells with average 90-day returns of +5.1%, indicating his sales do not demonstrate a consistent predictive signal. The company's fundamentals remain solid—$1.4B quarterly revenue with +14.8% annual growth and a P/E of 16.78—providing no obvious distress catalyst. The substantial size and discretionary nature of this sale, combined with the mixed historical timing patterns, warrant attention but do not present an unambiguous signal.

EVP & Chief Medical Officer Stein Steven H sells 5,233 INCY shares at $102.20; stock now at $105.98 (+24.1% in 30 days).

Stein Steven H sold 5,233 shares at $102.20 on 2025-11-05, reducing his holdings to 102,886 shares (-4.8%). The stock has appreciated significantly since the sale: +24.1% over 30 days and +35.2% over 90 days, now trading at $105.98 near its 52-week high. His prior four sales at INCY show mixed timing outcomes: two were followed by 90-day declines (well-timed), but two saw gains; his cross-ticker track record shows an average 90-day return of +5.1% after sells with a 50% well-timed rate, indicating no systematic outperformance. The stock trades at a reasonable 17.52 P/E with strong fundamentals (revenue $1.4B, net income $424.2M, +14.8% annual growth), and this modest sale reduces only a small portion of his substantial holdings.

EVP & CMO Stein sold 14,952 INCY shares at $68.47; stock down 17.0% from 52-week high, holds 106.6K post-sale.

Steven H Stein, EVP & Chief Medical Officer, sold 14,952 shares of INCYTE CORP at $68.47, reducing his holdings by 12.3% to 106.6K shares. The transaction occurred as INCY trades 17.0% below its 52-week high of $83.38, reflecting meaningful price deterioration over the past six months despite recent positive momentum (90-day change +18.9%). At INCY specifically, Stein's prior three sales show a mixed timing pattern: one sale in January 2025 was well-timed (the stock fell 21.9% in the subsequent 90 days), but his August 2024 and August 2023 sales both preceded gains (37.5% and 2.0% 30-day returns respectively), suggesting inconsistent foresight at this ticker. The company's fundamentals remain solid with revenue of $1,052,898,000.00 and net income of $158,203,000.00, though the P/E of 629.36 reflects minimal profitability relative to market valuation.

Stein (EVP & Chief Medical Officer) sold 12,352 shares at $72.69; holds 66,967 shares post-sale.

Stein Steven H, EVP & Chief Medical Officer, sold 12,352 shares of INCY at $72.69 on 2025-01-21, reducing holdings by 15.6% to 66,967 shares. The stock has since declined 13.2% from its 52-week high of $83.38 and is currently at $72.41, suggesting the sale occurred near intermediate strength. Across Stein's two prior INCY sales (August 2024 and August 2023), timing outcomes were mixed: the August 2024 sale preceded a 90-day rally of 37.5%, while the August 2023 sale preceded a 90-day decline of 17.6%. His cross-ticker track record shows an average 90-day return of 10.0% following sales with a 50% well-timed rate, indicating no consistent edge. The sale itself—occurring without disclosed scheduling flags and representing a material reduction of stake—merits investor attention given the executive's direct oversight of clinical and medical affairs, though the mixed timing history and absence of coordinated selling from other insiders limits the strength of any concern signal.

Chief Medical Officer Steven Stein sold 11,608 shares of INCY at $60.63 on 2024-08-12, reducing holdings by 11.4%.

Steven Stein, EVP & Chief Medical Officer, sold 11,608 shares at $60.63, bringing his holdings from 101,619 to 90,011 shares. His prior open-market sale at INCY on 2023-08-01 was well-timed at the 90-day mark, with the stock declining -17.6% following that trade. The current sale occurs with INCY trading at $61.18, approximately -10.8% from its 52-week high, and the stock has declined -4.8% over the last 30 days. The company reports a loss-making quarter (net income of $-444,601,000) alongside positive revenue growth of +8.9% and an elevated P/E of 119.96. This sale follows a pattern at this ticker, though the significance is tempered by the insider's limited position reduction in absolute terms.